Monthly Archives: February 2012

Verastem to Present at Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology”

Posted: Published on February 15th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NASDAQ: VSTM - News) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced that the company will present at the 2012 Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology.” The presentation is on February 19, 2012 at 2:00pm PT at the InterContinental San Francisco Hotel. About Verastem, Inc. Verastem, Inc. (NASDAQ: VSTM - News) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. Forward-looking statements: Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Verastem to Present at Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology”

Stem Cell Stocks: Mending Scarred Hearts

Posted: Published on February 15th, 2012

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. This is certainly exciting news considering heart failure is still the No. 1 cause of death in men and women. The study included 25 heart attack victims, 17 of whom got the stem cell treatment. Those patients saw a 50% reduction in cardiac scar tissue after one year, while the eight control patients saw no improvement. The procedure involves removing a tiny portion of heart tissue through a needle, cultivating the stem cells from that tissue, and reinserting them in a second minimally invasive procedure, according to Bloomberg. "If we can regenerate the whole heart, then the patient would be completely normal," said Eduardo Marban, director of Cedars-Sinai Heart Institute who was the study's lead author. "We haven't fulfilled that yet, but we've gotten rid of half of the injury, and that's a good start." Business section: Investing ideas Interested in investing in the promise that stem cell therapy holds? For a look at the investing landscape, we compiled a list of the 10 largest companies involved in stem cell therapy. Do … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stem Cell Stocks: Mending Scarred Hearts

Bone Repair Stem Cell Breakthrough Shows Promise

Posted: Published on February 15th, 2012

Editor's Choice Main Category: Stem Cell Research Article Date: 15 Feb 2012 - 8:00 PST email to a friend   printer friendly   opinions   Current Article Ratings: Patient / Public: 5 (2 votes) Healthcare Prof: According to a study published in the February issue of the STEM CELL Translational Medicine Journal , a world-first technique for generating adult stem cells (mesenchymal stem cells [MSCs]) has been developed by researchers at the University of Queensland. This new method can be used to repair bone and possibly other organs, and will considerably affect individuals suffering from a variety of serious diseases. Professor Nicholas Fisk, who leads the collaborative study between the UQ Clinical Research Center (UQCCR) and the UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN), explained: "We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature. The technique also worked on their less contentious counterparts, induced pluripotent stem cells. To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Bone Repair Stem Cell Breakthrough Shows Promise

Gene therapy for epilepsy could stop seizures

Posted: Published on February 15th, 2012

The researchers used gene therapy in rats to stimulate production of somatostatin, a seizure-stopping chemical that naturally occurs in the brain. The study was published in the February issue of the journal Neuroscience Letters. More than 3 million people in the United States have epilepsy, according to the Centers for Disease Control and Prevention. This lifelong disease is characterized by uncontrollable seizures and can keep people from living independently or holding jobs, particularly if they do not respond to seizure-controlling medication. Finding novel ways to prevent these seizures could help people with epilepsy live more normal, symptom-free lives, said Dr. Paul Carney, chief of the division of neurology in the UF College of Medicine department of pediatrics and senior author of the study. “For years people have focused only on treating the disease, not preventing the disease,” Carney said. “The mantra is no seizures, no side effects.” People with epilepsy tend to have lower levels of the hormone somatostatin, as do people with Alzheimer’s disease. Although somatostatin, which belongs to a group of protein-like molecules called neuropeptides, is present in the brains of people with epilepsy, scientists have shown that its levels decrease during seizures, said Rabia Zafar, the lead … Continue reading

Comments Off on Gene therapy for epilepsy could stop seizures

Kern Autism Network announces date for 17th Annual Autism Awareness Conference

Posted: Published on February 15th, 2012

Ramona Puget/Special to the Sun On Feb. 24, the Autism Society Chapter-Kern Autism Network will hold its 17th Annual Autism Awareness Conference at Hodel’s Banquet Room, 5917 Knudsen Drive, in Bakersfield. Our featured speaker is Emily Rubin, MS, CCC-SLP. Emily Rubin is the director of Communication Crossroads, a private practice in Carmel, Calif.  She is a speech-language pathologist specializing in Autism, Asperger’s Syndrome, and related social learning disabilities. As an adjunct faculty member and lecturer at Yale University, she has served as a member of their Autism and Developmental Disabilities Clinic.  She has also served as an instructor for the Communication Sciences and Disorders Department of Emerson College in Boston, Mass. where she has developed courses to prepare graduate level students for addressing the needs of children with autism and their families. She recently participated as a member of the American Speech-Language-Hearing Association’s Ad Hoc Committee on Autism Spectrum Disorders (ASD), a committee charged with developing guidelines related to the role of speech-language pathologists in the diagnosis, assessment, and treatment of ASD.  She lectures internationally and provides consultation to educational programs serving children and adolescents with autism and related developmental disorders. Autism is characterized by impaired social interaction, problems with … Continue reading

Comments Off on Kern Autism Network announces date for 17th Annual Autism Awareness Conference

Black Children Tend to be Diagnosed with Autism Later than White Children

Posted: Published on February 15th, 2012

Newswise — The rate of diagnosis for autism spectrum disorders (ASD) is the same among all racial groups — one in 110, according to current estimates. However, a study by a Florida State University researcher has found that African-American children tend to be diagnosed later than white children, which results in a longer and more intensive intervention. The reasons for later diagnoses include a lack of access to quality, affordable, culturally competent health care, according to Martell Teasley, an associate professor in Florida State’s College of Social Work who has conducted a comprehensive review of researchliterature on autism and African-American children. In addition, the stigmaattached to mental health conditions within the black community contribute to misdiagnoses of autism, and underuse of available treatment services. “There are no subjective criteria for diagnosing autism. Only brain scans can truly provide appropriate diagnoses, because we are dealing with biological and chemical imbalances in the brain,” Teasley said. “Not every child is going to have access to this kind of medical evaluation, particularly those who are indigent and don’t have health care funding.” Teasley examined ASD diagnosis and treatment strategies, and their effect on African-American families, in “Autism and the African-American Community,” a paper … Continue reading

Comments Off on Black Children Tend to be Diagnosed with Autism Later than White Children

Lindt Announces 2012 Autism Speaks Partnership Program

Posted: Published on February 15th, 2012

STRATHAM, N.H., Feb. 15, 2012 /PRNewswire/ -- Premium Swiss chocolatier, Lindt, announces today it is once again partnering with Autism Speaks to raise funds and awareness for autism during the Easter season. Lindt will support the world's leading autism science and advocacy organization through donations from sales of the iconic Lindt GOLD BUNNY.   Lindt GOLD BUNNY will support the Autism cause as it celebrates its 60th birthday in 2012. The #1 selling chocolate bunny in the United States*, Lindt GOLD BUNNY, is available in five sizes and three chocolate varieties: milk, dark and white chocolate. Starting today and continuing through Easter, April 8, 2012, Lindt will donate 10 cents to Autism Speaks for every Lindt GOLD BUNNY purchased in the United States, up to $100,000. Lindt will also donate $2 for every Easter basket sold at Lindt Chocolate Shops, Lindt.com and through Lindt Chocolate R.S.V.P., Lindt's home sales program. In addition, Lindt will donate $1 for every free Lindt Easter e-card sent, up to $5,000, to the organization, and up to $10,000 for consumers who use Pinterest to express their Easter traditions. Lindt is raising additional funds and awareness for Autism Speaks by hosting the third Lindt GOLD BUNNY Celebrity Auction. … Continue reading

Comments Off on Lindt Announces 2012 Autism Speaks Partnership Program

Operational research seeks benefit for stroke victims

Posted: Published on February 15th, 2012

The researchers are from the PCMD-based National Institute for Health Research (NIHR) Peninsula Collaboration for Health, Operational Research and Development (PenCHORD), which is part of the NIHR Peninsula Collaboration for Leadership and Applied Health Research and Care (PenCLAHRC). The study is investigating the whole process of emergency treatment that follows when a person suffers an acute stroke from a blocked artery in the brain. For most patients in this situation, the earliest possible administration of the clot-busting drug Alteplase can greatly improve their chances of recovery – called thrombolysis. The drug is currently licensed for delivery up to three hours from the onset of a stroke, but in that time the patient needs to call an ambulance, get to hospital, have a brain scan, and be assessed by specialists before receiving the treatment. The research team is working with healthcare professionals from SWASFT and the RD&E to analyse the various steps by which a stroke patient is identified, transported to hospital and treated. This includes paramedics, the emergency department (ED) team, triage nurses, the acute stroke team and the radiology department (which performs the brain scans). By investigating what happens 'on the ground', researchers have been able to create computer … Continue reading

Comments Off on Operational research seeks benefit for stroke victims

Fairhope Parkinson's patient enters film in contest to awareness of disease

Posted: Published on February 15th, 2012

FAIRHOPE, Alabama -- Susie Glickman is an amazing line dancer. It’s not because she can execute the Cupid Shuffle or the Electric Slide better than most. Rather, it is because every step takes extra effort now that this 67-year-old Fairhope woman has Parkinson’s disease. “I have it on my left side,” said Glickman, who was diagnosed with the chronic, progressive movement disorder in 2007. “I went in to see my doctor because my left arm didn’t feel like it was part of my body. When I found out it was Parkinson’s, I was shocked. I wanted to find out as much as I could about the disease.” At first glance, Glickman’s condition isn’t obvious. While moving a little slower these days, Glickman is fairly nimble. But this spunky grandmother struggles with tremors, weakness and balance issues. Turning pages can be tiresome — or downright impossible. Often, she succumbs to exhaustion. Nevertheless, Glickman considers herself lucky. “The mid 60s is the prime age to get Parkinson’s,” she said. “It usually progresses slowly when you are diagnosed in your 60s. But the younger you have it, the faster it progresses.” Glickman manages to move steadily while leading line-dancing classes in Mobile and … Continue reading

Posted in Parkinson's Treatment | Comments Off on Fairhope Parkinson's patient enters film in contest to awareness of disease

Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury

Posted: Published on February 15th, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)-- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that researchers have shown that Thymosin beta 4 (T?4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI), indicating that T?4 has promising therapeutic potential in patients with TBI.” The aims of the study were to test if T?4 treatment initiated 6 hours after traumatic brain injury in rats reduces brain damage and improves functional recovery. The rats were divided into two treatment groups and one placebo group. T?4 or placebo was systemically administered 6, 24, and 48 hours after injury. Compared with the placebo group, T?4 treatment initiated 6 hours post-injury statistically significant improvement of sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured brain tissue. The high dose of T?4 showed better beneficial effects compared with the low dose treatment. The research was conducted by Xiong Y, Zhang Y, Mahmood A, Meng Y, Zhang ZG, Morris DC, Chopp MJ in the Department of Neurosurgery at the Henry Ford Hospital System (HFHS) in Detroit, Michigan pursuant to a material transfer agreement between the hospital and RegeneRx Biopharmaceuticals, Inc. … Continue reading

Posted in Brain Injury Treatment | Comments Off on Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury